Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
OSR Holdings, Inc. (OSRHW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OSRHW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -52.38% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.03 - 0.09 | Updated Date 05/17/2025 |
52 Weeks Range 0.03 - 0.09 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
OSR Holdings, Inc.
Company Overview
History and Background
OSR Holdings, Inc. is a hypothetical company. This JSON provides a template structure for analyzing a real company.
Core Business Areas
- Software Development: Develops and sells software solutions for enterprises, focusing on cloud computing and data analytics.
- Consulting Services: Offers consulting services to help businesses optimize their IT infrastructure and implement new technologies.
- Hardware Sales: Sells hardware components and systems, including servers, workstations, and networking equipment.
Leadership and Structure
The company is led by a CEO and a board of directors. It is structured into departments based on business segments.
Top Products and Market Share
Key Offerings
- Cloud Analytics Platform: A cloud-based data analytics platform used by businesses to analyze large datasets. Market share is estimated at 15%. Competitors include Amazon Web Services, Microsoft Azure, and Google Cloud Platform.
- IT Consulting Services: Offers IT consulting to optimize company IT systems. Market share is estimated at 8%. Competitors include Accenture, Deloitte, and TCS.
Market Dynamics
Industry Overview
The IT industry is highly competitive and rapidly evolving, with increasing demand for cloud computing, data analytics, and cybersecurity solutions.
Positioning
OSR Holdings, Inc. is positioned as a mid-sized IT solutions provider, offering a range of services to businesses. Its competitive advantages include its specialized expertise and customer service.
Total Addressable Market (TAM)
The global IT market is valued at $5 trillion. OSR Holdings, Inc. is positioned to capture a small fraction of this TAM.
Upturn SWOT Analysis
Strengths
- Strong customer relationships
- Experienced management team
- Proprietary technology
- Diversified product portfolio
Weaknesses
- Limited brand recognition
- Smaller scale compared to competitors
- High dependence on key clients
- Slower innovation pace
Opportunities
- Growing demand for cloud computing
- Expansion into new markets
- Strategic acquisitions
- Partnerships with technology vendors
Threats
- Increased competition
- Rapid technological changes
- Economic downturns
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- IBM (IBM)
- Accenture (ACN)
- Tata Consultancy Services (TCS)
Competitive Landscape
OSR Holdings, Inc. competes with larger, more established players. It needs to differentiate itself through specialization and innovation.
Major Acquisitions
DataTech Solutions
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition to expand data analytics capabilities and customer base.
Growth Trajectory and Initiatives
Historical Growth: This section requires historical growth data.
Future Projections: This section requires analyst estimates for future growth.
Recent Initiatives: New software product and new cloud services
Summary
OSR Holdings, Inc. is a company with strong potential, fueled by a diversified product portfolio and strong customer relationships. It faces challenges from larger competitors and needs to focus on innovation and market expansion. Strategic acquisitions and partnerships will be critical for its future growth. The company's financial health and growth trajectory require further detailed financial analysis.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data used for demonstration purposes.
Disclaimers:
This analysis is based on hypothetical data and should not be used for investment decisions. A comprehensive financial analysis is required for informed investment choices.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OSR Holdings, Inc.
Exchange NASDAQ | Headquaters Bellevue, WA, United States | ||
IPO Launch date 2023-03-17 | Chairman & CEO Mr. Kuk Hyoun Hwang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.osr-holdings.com |
Full time employees 19 | Website https://www.osr-holdings.com | ||
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.